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Vesicular glutamate transporters (VGLUTs) are key molecules for the incorporation of glutamate in synaptic vesicles across the
nervous system, and since their discovery in the early 1990s, research on these transporters has been intense and productive. This
review will focus on several aspects of VGLUTs research on neurons in the periphery and the spinal cord. Firstly, it will begin
with a historical account on the evolution of the morphological analysis of glutamatergic systems and the pivotal role played by
the discovery of VGLUTs. Secondly, and in order to provide an appropriate framework, there will be a synthetic description of the
neuroanatomy and neurochemistry of peripheral neurons and the spinal cord. This will be followed by a succinct description of
the current knowledge on the expression of VGLUTs in peripheral sensory and autonomic neurons and neurons in the spinal cord.
Finally, this review will address the modulation of VGLUTs expression after nerve and tissue insult, their physiological relevance
in relation to sensation, pain, and neuroprotection, and their potential pharmacological usefulness.
1. How VGLUTs Became the
‘‘Gold Standard’’ for the Identification of
Glutamatergic Neurons
Before focusing on the presence and role of vesicular glu-
tamate transporters in neurons in the periphery and the
spinal cord, it is important to begin with some historical facts
on how it was that glutamatergic neurons were identified
in the nervous system. Several decades of research estab-
lished that glutamate is themajor excitatory neurotransmitter
in the mammalian central nervous system (CNS) [1] and
PNS, including dorsal root ganglion (DRG) and spinal cord
neurons [2, 3]. However, the morphological phenotyping of
glutamatergic neurons as well as glial cells was not to be a
trivial matter.
First in accomplishing amajor breakthroughwere Storm-
Mathisen, Ottersen, and their colleagues who, by means
of careful electron microscopy methodologies and meticu-
lous analysis, demonstrated glutamate-like immunoreactivity
(Li) in several areas of the mouse, rat, guinea pig, and
monkey brain and, importantly, its association to synapses
[4–6]. This pioneering work led to the distinction of a
“transmitter pool” in glutamatergic terminals, a “metabolic
pool” in nonglutamatergic neurons, and a “glial pool” [7–
9]. It also prompted the immunohistochemical analysis in
sensory neurons, using antibodies against glutamate [10–14].
Subsequent methods to identify glutamatergic neurons were
based on the immunohistochemical detection of enzymes
like glutaminase, involved in the synthesis of glutamate [15,
16]. This was being reliably done for other neurotransmitters
such as catecholamines, serotonin, acetylcholine, and also
GABA [17]. More indirect approaches, like the identification
of excitatory amino acid transporters (EAATs) located at
the cell membrane, both of neurons and astrocytes, and
critical for the removal of glutamate released at the synaptic
cleft, also emerged [18, 19]. However, since glutamate is a
major participant in cell metabolism, even for the synthesis
of the inhibitory neurotransmitter GABA [7, 20], and not
always the visualization of associated molecules guarantees
the glutamatergic nature of neurons, an ideal marker was still
sought.
A second breakthrough took place in themid 1990s, when
Ni and collaborators [21] revealed the presence of a brain-
specific Na+-dependent inorganic phosphate transporter in
the brain of rat pups. Further research showed that this
transporter was specific to synaptic vesicles, acted as a
2 ISRN Neurology
vesicular glutamate transporter (VGLUT), and hence was
termed VGLUT
1
[22, 23]. Soon afterwards, VGLUT
2
[24–
30] and VGLUT
3
[31–33] were discovered and characterized.
Importantly, transfection of GABAergic neurons with DNA
encoding VGLUT
1
[23] or VGLUT
2
[29] conferred the
capacity to release both glutamate and GABA, confirming
their role in glutamate loading of synaptic vesicles.
Thus, it was that the discovery of VGLUTs and the
development of selective antibodies and in situ hybridization
probes for their detection became the “gold standard” for the
characterization of glutamatergic neurons in the brain and
brainstem [34–37], the spinal cord [38–43], the peripheral
nervous system (PNS) [30, 34, 36, 38, 44–66], and even
glia [67–70]. It should, however, be mentioned that neurons
coexpressingVGLUT
1
[71] or VGLUT
3
[31] and theGABAer-
gic marker glutamate decarboxylase have been identified in
developing rat hippocampal granule cells (GC), in adult rat
hippocampal GCs under intense ionotropic or trophic factor
stimulation [71] and in interneurons in the stratum radiatum
of the hippocampus [31].
2. Some Neuroanatomical and
Neurochemical Details of Peripheral
Neurons and the Spinal Cord
2.1. Sensory and Autonomic Ganglia. Sensory impulses,
including pain, originating in the surface of the body (e.g., the
skin) or deeper structures (e.g., muscles, joints, and viscera)
are transmitted to the spinal cord byway of peripheral nerves.
These are contributed by thousands of axons produced by
sensory neurons (also called primary afferent neurons) con-
tained in theDRGs and cranial ganglia [3].The greatmajority
of studies analyzing the characteristics of primary afferent
neurons focus on “nonvisceral” DRGs, more specifically the
4th and 5th lumbar (L4-5) DRGs, which typically innervate
muscles and skin of the leg and foot by way of the sciatic
nerve, both in rodents and humans [72].
In contrast, visceral organs are characterized for their
innervation by two different “extrinsic” currents: (1) the
spinal current, including the pelvic (PN) and the lumbar
splanchnic (LSN) nerves [73, 74] and (2) the cranial current,
contributed by the vagus nerve [75]. These two currents
originate in “visceral” DRG and cranial ganglia neurons,
identified by means of retrograde tracing from their periph-
eral nerve endings in thoracic, abdominal, and pelvic organs.
In particular, the PN and the LSN innervating the colorectum
or the urinary bladder in rat [73, 76] and mouse [73, 76,
77] carry axons derived from: (1) peripheral projections of
thoracolumbar (TL; T8-L1) and lumbosacral (LS; L6-S1)DRG
neurons [73, 78]; (2) postganglionic projections of sympa-
thetic neurons contained in the lumbar sympathetic chain
(LSC); and (3) sympathetic and parasympathetic neurons
present in the “mixed” major pelvic ganglion (MPG) [79–81].
In addition, and unlike other tissues and organs in the body,
the gut is also provided with its own “intrinsic” autonomic
innervation. This includes sensory and motor autonomic
neurons found in the myenteric and submucosal plexuses,
from the esophagus to the anus, and collectively referred to
as enteric neurons, creating an intrinsic neuronal network
[81, 82].
In normal conditions, rodent nonvisceral DRG neurons
express a multiplicity of neurotransmitters and receptors,
often in different combinations, and are generally consid-
ered glutamatergic [83, 84]. Three main subpopulations of
DRG neurons have been characterized, including: (1) large
and medium-sized neurons expressing NF-200; (2) small
and medium-sized neurons expressing the calcitonin gene-
related peptide (CGRP) and termed “peptidergic”; and (3)
small and medium-sized “nonpeptidergic” neurons express-
ing components of the receptor for the glial-derived neu-
rotrophic factor and binding of isolectin B4 (IB4; from the
plant Griffonia simplicifolia I) to neuronal glycoproteins and
glycolipids [83, 84]. However, the “nonpeptidergic” term
should only be applied to subpopulations lackingCGRP, since
colocalization between IB4 and CGRP has been shown in
rats [85] and mouse [86]. Interestingly, and highlighting the
neurochemical complexity of DRG neurons, subpopulations
of nonvisceral DRG neurons, lacking both neuropeptides
and/or IB4 while expressing the noradrenergic marker tyro-
sine hydroxylase (TH) [87] or the neuropeptide tyrosine
receptor type 2 (Y2R) [88], have also been described.
Several molecules involved in pain sensing (nociception)
are expressed by nonvisceral DRG neurons, including the
already mentioned CGRP, the transient receptor potential
cation channel, subfamily V,member 1 (TRPV1) [89], the P2X
purinoceptor 3 (P
2
X
3
) [90], or the sodium channel NaV1.8
[91]. Finally, other transmitter candidates in DRG neurons
are the nucleotide adenosine-triphosphate (ATP) [92, 93], the
“gaseous” transmitter nitric oxide [93, 94], and neurotrophic
factors such as the glial- and the brain-derived neurotrophic
factors [83].
Visceral DRG neurons, like nonvisceral ones, are clas-
sically described as being glutamatergic [14] and normally
coexpress a variety of molecules, including neuropeptides
[95].Thus, CGRP is synthesized by rat [76, 96–98] andmouse
[76, 77] visceral sensory neurons. TRPV
1
, P
2
X
3
, IB4 [73], and
even TH [99] are also expressed by visceral sensory neurons.
Autonomic neurons aremorphologically characterized as
sympathetic or parasympathetic, based on their expression of
noradrenaline (using TH or the norepinephrine transporter
type 1 for identification) or acetylcholine (using choline
acetyltransferase or the vesicular acetylcholine transporter
(VAChT) for identification), respectively. However, it should
be noted that some sympathetic neurons have also been
shown to coexpress acetylcholine and neuropeptides [80,
100–102]. Finally, different subpopulations of enteric neurons
in the myenteric and submucosal plexuses typically express
markers such as TH, VAChT, nitric oxide synthase, and
several neuropeptides [103].
2.2. Spinal Cord. Peripheral stimuli processed by primary
afferent neurons are transferred to the spinal cord by way
of their central axons (dorsal roots). In this manner, they
penetrate the gray matter, which is divided into 9 laminae,
from dorsal to ventral, and an area around the central canal
(area X), as originally characterized through analysis of the
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morphology and arrangement of Nissl-stained cell bodies
in transverse sections of the cat spinal cord [104]. Neurons
in each laminae are arranged in a complex but ordered
manner, based on morphology, neurochemical composition,
and specific sensory modalities [105–107]. Thus, lamina I,
the most superficial of all, receives cutaneous A𝛿- and C-
fibers [108–111] and muscle and articular afferents [112, 113],
as well as visceral afferents [114–116]. Laminae II, subdivided
into outer (IIo) with densely packed cells and inner (IIi)
[117], receives predominantly unmyelinated C-fiber afferents
[110, 118–120]. In addition, A𝛿-fibers terminate mostly in
lamina IIo [121], and some cutaneous mechanoreceptive A𝛽-
fibers reach lamina IIi via lamina III [120, 122–125]. A𝛼/𝛽-
fibers are the main afferent projections to laminae III–VI
[110, 112, 123–129]. However, a subpopulation of fine C-fibers
also penetrates deeply in the dorsal horn, into lamina III
[98, 110, 112, 118, 130–132]. Finally, the area X receives a
considerable input of visceral afferents [98, 115, 132–134],
although terminals contributed by somatic afferents are also
present [129, 135].
3. Expression of VGLUTs in Peripheral
Visceral and Nonvisceral Glutamatergic
DRG and Cranial Sensory Neurons
3.1. Somatic Expression of VGLUTs. The expression of
VGLUT
1
mRNA in large and somemedium-sized L4-5 DRG
neurons was first shown (although not quantified) in the rat
[48, 51]. Subsequent analysis in the mouse [53, 54] revealed
presence ofVGLUT
1
-IRneurons in 12% to 37%of nonvisceral
DRG neurons (Figure 1, Table 1), while its transcript has been
detected in ∼45% of L4-5 DRG neurons of large and medium
size [136]. Immunohistochemical signal for VGLUT
1
is also
observed in large and medium-sized visceral DRG neurons
projecting to the mouse colorectum (12% [61]) and urinary
bladder (32% [62]) (Figure 1, Table 1). Variations between the
reported proportions of VGLUT
1
-expressing DRG neurons
may depend on: (1) differences in protein and gene regulation
between DRG levels (TL versus LS versus L4-5); (2) the use of
different VGLUT
1
antibodies/probes, immunohistochemical
and in situ hybridization techniques or even mouse strains;
and (3) especially when it comes to transcript versus protein
mismatches, differential regulatory mechanisms.
In contrast to VGLUT
1
, VGLUT
2
has been found in a
large proportion of DRG neurons, spanning different cell
soma sizes (Figure 1, Table 1), as initially shown in immuno-
histochemical studies in DRGs targeting the rat ileum [44]
or in situ hybridization analysis of lumbar nonvisceral DRGs
[51]. In the mouse, from ∼65% [54] and up to 90% [137]
VGLUT
2
-IR NPs are present in L4-5 DRGs. Even higher
percentages of VGLUT
2
-IR NPs have been described in
visceral DRG neurons innervating the colorectum [61] or the
urinary bladder [62]. Confirming the abundance of VGLUT
2
in DRG neurons, up to 70% [136] or 82% [137] of mouse L4-5
DRG neurons have been shown to express VGLUT
2
mRNA.
Identifying VGLUT
3
in peripheral sensory neurons has
been more difficult than for the other VGLUTs, mainly due
to the unavailability of antibodies that reliably labelled DRG
neurons (in fact, this is still the case today). However, using
transgenic mice expressing the enhanced green fluorescent
protein (EGFP) under the control of VGLUT
3
regulatory
sequences, Seal et al. [66] showed that around 10-11% of
nonvisceral lumbarDRGneurons expressVGLUT
3
[66].This
has been recently confirmed by in situ hybridization, with
detection of VGLUT
3
mRNA in ∼17% of nonvisceral DRG
NPs [65, 136], and through the identification of ∼19% of
transgenic adult mouse nonvisceral DRG NPs expressing the
reporter gene Tomato, under the control of the VGLUT
3
promoter [65] (Figure 1, Table 1). VGLUT
3
is also present
in subpopulations of visceral sensory neurons innervating
both the colorectum (∼10%, Figure 1, Table 1) or the urinary
bladder (∼18% [62]). VGLUT
3
appears mostly expressed in
small and medium-sized adult DRG NPs [62, 65, 66, 136].
However, a transient versus persistent expression of VGLUT
3
has been proposed, where the transporter is found in large
and medium-sized myelinated nonvisceral DRG neurons
only during prenatal stages, with the small neuron population
remaining VGLUT
3
-expressing during the adult life [65].
In DRGs projecting to visceral organs, an additional
peculiarity is observed. Thus, TL and LS DRGs innervating
the mouse colorectum [61] or the urinary bladder [62]
contain different proportions of neurons expressing VGLUT
1
orVGLUT
3
(see Table 2), whilst VGLUT
2
is equally abundant
at bothDRG levels [62]. Similar variationswere also observed
for other markers. For instance, the transient receptor poten-
tial cation channel, subfamily A, member 1 (TRPA
1
) mRNA
is abundant in mouse TL bladder neurons but scarce in
LS bladder neurons [138]. On the contrary, TH protein is
expressed in threefold (colorectum) and fivefold (urinary
bladder) greater proportions in mouse LS DRGs than in
TL DRGs [62]. Interestingly, it has been postulated that
differences in neurochemical expression between DRG levels
could have an impact in the electrophysiological properties of
TL and LS visceral afferent neurons [139, 140], as shown in the
mouse colorectum, where a higher expression of TRPV
1
in
TL than in LSDRGs correspondswith amore robust response
to applied capsaicin in colorectal TL nerve terminals [140].
The frequent association of VGLUT
2
-Li to the plasma
membrane in nonvisceral [54] and visceral [61, 62] DRG
neurons (Figure 1) has raised the question of if somatic
glutamatergic release was possible in these neurons [54].
Accumulating evidence suggests that messenger molecules
in general are released from the somatic compartment of
the neuron [146], including DRG neurons [147–150]. Thus,
neuropeptides [147, 148], ATP [149], and even genetically
expressed macromolecular tracers in DRG neurons [150]
have been shown to undergo somatic release. Interestingly,
recent studies in Xenopus oocytes transfected with VGLUT
2
suggest that this transporter can be found in two different
states: (1) serving the traditional role of packaging glutamate
into synaptic vesicles for Ca2+-dependent exocytosis, and (2)
participating in Ca2+-independent leakage when present in
the plasma membrane [151]. Moreover, this dual role appears
to be also true for VGLUT
1
andVGLUT
3
[151].Whether such
states are also a feature in sensory neurons, and VGLUTs
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VGLUT1
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(a)
VGLUT2
L4-5
(b)
VGLUT3
L4-5
(c)
L4-5
VGLUT1 + CGRP
(d)
L4-5
VGLUT2 + CGRP
(e)
EGFP + CGRP
L4-5
(f)
VGLUT1 + IB4
L4-5
(g)
VGLUT2 + IB4
L4-5
(h)
VGLUT2
L4-5
(i)
VGLUT1 + FB + CGRP
Colorectum
(j)
U. bladder
VGLUT2 + FB + CGRP
(k)
EGFP + FB + CGRP
Colorectum
(l)
Figure 1: Broad VGLUT expression in mouse visceral and nonvisceral DRG neurons. Bright-field ((a)–(c)) and immunofluorescence ((d)–(l))
photomicrographs of DRG sections incubated with VGLUT
1
, VGLUT
2
, or VGLUT
3
antisense riboprobes ((a), (b), (c), resp.) or VGLUT
1
((d),
(g), (j)), VGLUT
2
((e), (h), (i), (k)), or EGFP ((f), (l)) antibodies (EGFP, used as a reporter of VGLUT
3
expressing neurons). Colocalizations
with CGRP ((d)–(f), (j)–(l)) or IB4 ((g), (h)) are also shown. Colorectum ((j), (l)) or urinary bladder (k)DRGneurons are exposed by presence
of the retrograde tracer FB ((j), (k), (l)). ((a)–(c)) VGLUT transcripts are detected in nonvisceral DRGs, VGLUT
1
mostly in large andmedium-
sized NPs (black double arrowheads in (a)), VGLUT
2
in many NPs spanning different cell body sizes (black double arrowheads in (b)), and
VGLUT
3
in a discrete number of usually small and somemedium-sizedNPs (black double arrowheads in (c)). ManyNPs lacking VGLUTs are
also detected (white double arrowheads in (a)–(c)). ((d)–(f)) The distribution of VGLUT
1
- (arrowheads in (d)) VGLUT
2
- (arrowheads and
black double arrowheads in (e)), and EGFP-IR (arrowheads in (f)) nonvisceral DRGNPs correlates with the transcript counterparts shown in
(a)–(c).While most CGRP-expressing nonvisceral DRGNPs coexpress with VGLUT
2
(black double arrowheads in (e)), VGLUT
1
-, VGLUT
3
-
(arrowheads in (d), (f)), and CGRP-IR (arrows in (d), (f)) NPs virtually always appear as independent subpopulations. Many VGLUT
2
-IR
DRG NPs lacking CGRP are also detected (arrowheads in (e)). ((g), (h)) IB4 is virtually always present in VGLUT
2
-IR nonvisceral DRG
NPs (black double arrowheads in (h)), while many other VGLUT
2
-only NPs are also observed (arrowheads in (h)). In contrast, VGLUT
1
-
(arrowheads in (g)) and IB4-expressing (arrows in (g)) DRGNPs always belong to different subpopulations. (i) VGLUT
2
-membrane staining
is detected in a number of nonvisceral DRG NPs (small arrowheads). ((j)–(l)) VGLUT
1
- (arrowheads and with double arrowhead in (j)),
VGLUT
2
- (arrowheads and black double arrowheads in (k)), and EGFP-IR (arrowheads and white double arrowheads in (l)) are detected in
visceral DRG NPs, with a similar cell soma distribution as observed for nonvisceral DRGs. CGRP-IR visceral DRG NPs are virtually always
VGLUT
2
-IR (black double arrowheads in (k)), while NPs expressing the peptide (arrows in (j), (l)) and VGLUT
1
(arrowheads and double
arrowheads in (j)) or EGFP-IR NPs (arrowheads and double arrowheads in (l)) belong to different subpopulations. Scale bars: 50 𝜇m ((c) =
(a), (b); (h) = (d)–(g); (k) = (j); (l)); 20𝜇m (i). Data in figures (f) and (l) is previously unpublished, and the tissue has been processed according
to the immunohistochemical procedures described in [54, 60–62].
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Table 1: Percentage of DRG neurons (visceral or nonvisceral) expressing VGLUTs (protein and mRNA).
VGLUT Species Percent nonvisceral afferents Percent visceral afferents (targetorgans)
VGLUT1 protein
Mouse ∼37% [53]; ∼12% [54] ∼12% (Colorectum [61])
∼32% (U. Bladder [62])
Rat Detected, not quantified [48] NE (Colorectum, U. Bladder)
VGLUT1 mRNA
Mouse ∼40% [136] NE (Colorectum, U. Bladder)
Rat Detected, not quantified [48] NE (Colorectum, U. Bladder)
VGLUT2 protein
Mouse ∼65% [54] ∼97% (Colorectum [61])
∼94% (U. Bladder [62])
Rat NE
Detected, not quantified (Stomach
and Ileum [44])
NE (Colorectum, U. Bladder)
VGLUT2 mRNA
Mouse ∼70% [136] NE (Colorectum, U. Bladder)
Rat NE NE (Colorectum, U. bladder)
VGLUT3 Protein
Mouse ∼10% [66]; ∼19% [65] ∼10% (Colorectum
∗)
∼18% (U. Bladder [62])
Rat NE NE (Colorectum, U. bladder)
VGLUT3 mRNA
Mouse ∼17% [136]; ∼16% [65] NE (Colorectum, U. Bladder)
Rat NE NE (Colorectum, U. Bladder)
NE: not evaluated; ∗unpublished data; tissue has been processed and NPs quantified according to references [54, 60–62].
Table 2: Percentage of colorectal or urinary bladder DRG neurons
expressing VGLUTs protein.
Target organ DRG level VGLUT1 VGLUT2 VGLUT3
Colorectum Thoracolumbar ∼15% [61] ∼98% [61] ∼17%
∗
Lumbosacral ∼8% [61] ∼97% [61] ∼4%∗
Urinary bladderThoracolumbar ∼39% [62] ∼94% [62] ∼28% [62]
Lumbosacral ∼26% [62] ∼94% [62] ∼8% [62]
∗Unpublished data; tissue has been processed and NPs quantified according
to references [54, 60–62].
facilitated any form of somatic glutamatergic release remains
to be established.
Finally, cranial sensory neurons are richly provided with
VGLUTs, and their expression varies between target organs
(Table 3).
3.2. Neurochemical Phenotype of VGLUT-Expressing DRG
Neurons. As described in Section 2.1, DRG neurons can be
divided into peptidergic and nonpeptidergic. VGLUT
1
-IR
DRG neurons, either nonvisceral [48, 53, 54] or visceral [61,
62] appear to be nonpeptidergic and lacking IB4 (Figure 1,
Table 4) or TH (Figure 2), as shown in rat [48] and mouse
[53, 54, 61, 62]. Li et al. [46] and Alvarez et al. [50], however,
have reported that VGLUT
1
may be found in neuropeptide
containing afferents terminating in the laminae I and II of
the rat dorsal horn.This suggests that some peptidergic DRG
neurons in the rat may synthesize low levels of VGLUT
1
, only
detected in primary afferent terminals in the spinal cord but
not in the larger cell bodies, where the immunohistochemical
signal may be “diluted”.
Sharing some similarities with VGLUT
1
, VGLUT
3
is
expressed in nonvisceral DRG neurons lacking CGRP, only
in around 7% of those binding IB4 [66] (Figure 1, Table 4),
but in most cases coexpressing with TH (Figure 2), the latter
being typically detected in nonpeptidergic, nonvisceral DRG
neurons [87]. Accordingly, in visceral DRGneurons targeting
either the colorectum (Figure 1) or the urinary bladder [62],
VGLUT
3
has only been detected in the nonpeptidergic
subpopulation (Table 4).
In contrast to VGLUT
1
or VGLUT
3
, a considerable
number of VGLUT
2
-IR DRG neurons coexpress CGRP or
IB4 in nonvisceral [54] as well as visceral [61, 62] mouse
DRGs (Figure 1, Table 4). Conversely, virtually all DRG neu-
rons expressing CGRP or binding IB4 synthesize VGLUT
2
.
This is in agreement with the considerable colocalization of
VGLUT
2
and IB4 previously described in primary afferents
in the rat dorsal horn [45, 46, 49, 50] and mouse DRG
neurons [53] and the previously shown colocalization of glu-
taminase with CGRP [152] and of glutamate-Li with CGRP
or substance P in rat [11, 14, 153]. Accordingly, colorectal—
[61] and urinary bladder-projecting [62] DRG neurons often
coexpress VGLUT
2
and CGRP (Figure 1, Table 4). Finally,
virtually all VGLUT
2
-expressing nonvisceral DRG neurons
in the mouse express TH (Figure 2), and in rat [154]
and mouse [155], colocalization with TRPV1 has also been
reported.
3.3. VGLUTs Colocalization in Cranial and DRG Neurons. It
is now clear that at least some neurons in the nervous system
express more than only one type of VGLUT. This was not
the understanding when VGLUTs were first described. Thus,
initial observations in the adult mammalian CNS showed a
complementary distribution for VGLUT
1
and VGLUT
2
[26,
28, 30, 156, 156, 157]. Moreover, this complementarity seemed
to extend to the synaptic level, where both VGLUTs appeared
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Table 3: Presence of VGLUTs protein in cranial sensory neurons and their projections (upper part, VGLUTs presence in retrogradely traced
cranial sensory neurons; lower part, immunohistochemical detection of VGLUTs in nerve terminals of cranial sensory neurons).
Organ/species Cranial ganglia VGLUT1 VGLUT2 VGLUT3
Rat stomach [44, 141] Nodose + + NE
Rat aortic depressor nerve [141, 142] Nodose Not detectable + +
Guinea pig trachea [58] Nodose + + NE
Mouse tongue [143] Geniculate + + NE
Rat cornea [45] Trigeminal + + NE
Organ/species Nerve/terminals VGLUT1 VGLUT2 VGLUT3
Rat pleura [56] Laminar endings + + NE
Rat heart [141] Cardiac vagal afferents + Not detectable Not detectable
Guinea pig trachea [58] Cough mechanoreceptors + + NE
Mouse tongue [143] Taste Buds + + NE
Rat masseter muscle [144] Mesencephalic projections + NE NE
Rat cornea [59] Trigeminal + + NE
Human teeth [63] Trigeminal + + NE
Rat lung [145] Pulmonary neuroepithelial bodies NE + NE
+: present; NE: not evaluated.
Table 4: Percentage of DRG neurons (visceral or nonvisceral) expressing VGLUTs and CGRP, IB4, or other VGLUTs.
Colocalization Species Percent nonvisceralafferents Percent visceral afferents (target organ)
VGLUT1 also CGRP
Mouse Not detectable[53, 54] Not detectable (Colorectum [61], U. Bladder [62])
Rat Not detectable [48] NE (Colorectum, U. bladder)
VGLUT1 also IB4
Mouse Not detectable[53, 54] NE (Colorectum, U. Bladder)
Rat NE NE (Colorectum, U. Bladder)
VGLUT2 also CGRP
Mouse ∼31% [54] ∼81% (Colorectum [61])
Rat NE ∼53% (U. Bladder [62])
VGLUT2 also IB4
Mouse ∼42% [54] NE (Colorectum, U. Bladder)NE (Colorectum, U. Bladder)
Rat NE NE (Colorectum, U. Bladder)
VGLUT3 also CGRP
Mouse Not detectable [66] Not detectable (Colorectum∗, U. Bladder [62])
Rat NE NE (Colorectum, U. Bladder)
VGLUT3 also IB4
Mouse ∼7% [66] NE (Colorectum, U. Bladder)
Rat NE NE (Colorectum, U. Bladder)
VGLUT2 also VGLUT1 Mouse ∼14% [54] Highly likely (Colorectum [61], U. Bladder [62])
VGLUT2 also VGLUT3 Mouse ∼100%∗ Highly likely (Colorectum [61], U. Bladder [62])
VGLUT1 also VGLUT3 Mouse Not detectable∗ NE (Colorectum, U. Bladder)
VGLUT2 also VGLUT1
VGLUT2 also VGLUT3
VGLUT1 also VGLUT3
Rat NE NE (Colorectum, U. Bladder)
NE: not evaluated; ∗unpublished data; tissue has been processed and NPs quantified according to references [54, 60–62].
segregated in physiologically different synapses in the CNS
[26, 30, 158, 159]. However, the finding of glutamatergic
terminals in the rat hippocampus, containing both VGLUT
1
and VGLUT
2
, suggested the possibility of a supplementary
distribution [157].
Such a possibility is in fact also a feature in the periphery.
Thus, in rat trigeminal ganglia [45] and nonvisceral DRGs
[51], coexpression of VGLUT
1
and VGLUT
2
protein or
mRNA has been reported in a subpopulation of neurons,
respectively. This was confirmed in mouse (Table 4), were
a moderate coexpression of VGLUT
1
and VGLUT
2
was
shown in some medium-sized and large nonvisceral DRG
neurons [54]. Coexpression of VGLUT
3
and VGLUT
2
(but
not VGLUT
1
) is also detected in nonvisceral DRGs (Figure 2,
Table 4). Finally, the overwhelming presence of VGLUT
2
in virtually all colorectal [61] and urinary bladder [62]
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Figure 2: Frequent coexpression of VGLUT2 or EGFP (VGLUT3) with TH or VGLUT2 and EGFP in mouse nonvisceral DRG neurons.
Immunofluorescence photomicrographs of nonvisceral DRG sections incubated with VGLUT
1
((a), (d)), VGLUT
2
((b), (e)), or EGFP
antibodies ((c), (d), (e)). ((a)–(c)) While virtually no VGLUT
1
-IR (arrowheads in (a)) DRG NPs coexpress with TH (arrows in (a)), most
VGLUT
2
- or EGFP-IR NPs present with TH-Li (black double arrowheads in (b), (c)). Abundant VGLUT
2
- (arrowheads in (b)), EGFP-
(arrowheads in (c)), and some TH-only (arrows in (c)) expressing NPs are also detected. ((d), (e)) Lack of coexpression is observed between
VGLUT
1
(arrowheads in (d)) and EGFP (arrows in (d)). In contrast, EGFP is virtually always coexpressed with VGLUT
2
in DRGNPs (double
black arrowheads in (e)).Many otherVGLUT
2
-only expressingDRGNPs are also detected (arrowheads in (e)). Scale bars: 30 𝜇m((c) = (a), (b);
(e) = (d)). Data in figures (a)–(e) is previously unpublished, and the tissue has been processed according to the immunohistochemical procedures
described in [54, 60–62].
DRG neurons, indirectly implies a considerable degree of
colocalization with VGLUT
1
or VGLUT
3
.
How coexpression of two VGLUTs in the same neuron
influences its role in neurotransmission is not yet known. It
has, however, been suggested that VGLUT expressionmay be
associated with different patterns of neurotransmitter release.
Thus, VGLUT
1
is normally expressed in CNS neurons with
low probability release (climbing fibers in the cerebellum),
whereas VGLUT
2
would be associated to those with high
probability (parallel fibers in the cerebellum) [160]. Whether
the type of VGLUT expressed in a single DRG neuron or the
coexpression of more than one VGLUT have an impact on
release probability remains to be established.
3.4. VGLUTs in the Peripheral Projections of Cranial and DRG
Neurons. VGLUTs in peripheral nerves were first identified
in rat, mouse [161, 162], and guinea pig [163] esophageal
intraganglionic laminar endings (IGLEs), dependent on vagal
afferents, and shown to contain VGLUT
2
. VGLUT
1
was also
found in esophageal IGLEs in the guinea pig [163] and rat
[164] but not the mouse [165]. Subsequent studies revealed
presence of VGLUTs in peripheral nerves in many other
locations in the upper body (Table 2).
VGLUTs are also present in axonal terminations of
abdominopelvic organs in the guinea pig [166] and mouse
[61, 62, 167], where VGLUT
2
appears to be the main player.
Thus, VGLUT
2
-Li is found in abundant varicosities around
VGLUT
2
-negative mouse colorectal myenteric plexus neu-
rons (Figure 3) [61], in agreement with observations in the
guinea pig [166] and mouse rectum [167], and supporting
data on guinea pig small intestine showing glutamate-Li with
a similar distribution [168]. VGLUT
2
is also detected in an
overwhelming number of nerve endings terminating in the
urinary bladder (Figure 3) [62]. Unlike VGLUT
2
, VGLUT
1
is
only found in very few nerve fibers in the mouse colorectum
[61], and in a small number of fibers in the urinary bladder,
mostly within the muscular layers of this organ (Figure 3)
[62]. Discrete VGLUT
1
expression has also been reported
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Figure 3: Distribution of VGLUT-containing peripheral nerve fibers in mouse visceral organs and the MPG. Immunofluorescence ((a)–(c),
(g)–(i)) and bright-field ((d)–(f)) photomicrographs of sections of the colorectum ((a)–(c), (d)–(f)) the urinary bladder ((g), (h)) and the
MPG (i), incubated with VGLUT
1
((a), (h)) or VGLUT
2
((b), (c), (h), (i)) antibodies or VGLUT
1
, VGLUT
2
or VGLUT
3
antisense riboprobes
((d), (e), (f), resp.). In (i), a colorectal MPG NP is exposed by its content of fast blue (asterisk). In ((a), (c), (g) and (h)), the position of
the lumen is indicated by a white asterisk. ((a)–(c)) Isolated VGLUT
1
-IR nerve fibers are detected in the mucosal layer of the colorectum
(double arrowhead in (a)), in contrast to the abundance of VGLUT
2
-IR nerve fibers in the myenteric plexus (black double arrowheads in
(b)), the interconnecting nerve fibers (white double arrowheads in (b)), and the mucosal layer (white double arrowheads in (c)). ((d)–(f))
Only a number of VGLUT
2
mRNA-expressing myenteric plexus NPs are detected in the mouse colorectum (black double arrowheads in (e)),
in contrast to the absence of VGLUT
1
- or VGLUT
3
mRNA-expressing NPs in such ganglia ((e), (f), resp.). ((g), (h)) While a small number
of VGLUT
1
-IR nerve fibers are detected in the urinary bladder wall, especially in the muscular layer (black double arrowheads in (g)) and
some in the submucosa (white double arrowhead in (g)), VGLUT
2
-IR nerve fibers are abundant and present throughout the whole thickness
of the organ, including the muscular (black double arrowheads in (h)) and submucosal and mucosal layers (white double arrowheads in
(h)). (i) A colorectal MPG NP is surrounded by a dense VGLUT
2
-IR basket (white double arrowheads). Scale bars: 50 𝜇m ((a)–(c), (g), (h));
25 𝜇m ((d)–(f)); 10 𝜇m (i). Figures (d) and (e) are reproduced in part, and with permission, from reference [61]. Data in figure (f) is previously
unpublished, and the tissue has been processed according to the in situ hybridization procedures described in [60, 61].
in the Pacinian corpuscle and associated neurites in the cat
mesentery [55].The disparate representation of VGLUT
1
and
VGLUT
2
in peripheral nerves terminating in visceral organs
is supported by Olsson et al. [166], showing that ∼3% of
anterogradely traced guinea pig rectal nerve varicosities ter-
minating in the myenteric plexus contain VGLUT
1
, whereas
∼11% exhibit VGLUT
2
-Li.
In the skin, the immunohistochemical presence of
VGLUT
1
and VGLUT
2
has been studied in mouse [54]
and rat [52, 169]. Thus, VGLUT
1
is discretely expressed
in dermal and epidermal nerves of the glabrous (hairless)
skin, in the piloneural complex in hairy skin of mouse
(Figure 4) [54], and in rat primary afferent endings in the
muscle spindles in the triceps surae muscle [52]. Conversely,
VGLUT
2
is detected not only in piloneural complexes in
hairy skin, but also in numerous nerve endings terminating
in the glabrous hindpaw skin (Figure 4), both in deep dermal
bundles as well as in close relation to the epidermis, often
contacting VGLUT
2
-IR Merkel cells [54]. The presence of
both VGLUT
1
- and/or VGLUT
2
-IR fibers in the piloneural
complex suggests their origin in glutamatergic DRG neurons
producing myelinated D-fibers [170].
Peripheral nerve endings containing VGLUT
3
have been
more difficult to analyze than those expressing VGLUT
1
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Figure 4: Distribution of VGLUT-containing peripheral nerve fibers in the mouse skin. Immunofluorescence photomicrographs of sections of
the glabrous ((a), (c)) and hairy skin ((b), (d)) incubated with VGLUT
1
((a), (b)) or VGLUT
2
((c), (d)) antibodies. ((a), (b)) VGLUT
1
-IR nerve
fibers are discretely observed in the glabrous (double arrowheads in (a), showing nerve fibers in close proximity to the epidermis) and the
hairy skin (black double arrowheads in (b), showing the follicular neural network; white double arrowheads showing fibers lying in the basal
membrane of the epidermis). ((c), (d)) Abundant VGLUT
2
-IR nerve fibers are detected in the glabrous (arrowheads in (c), showing nerve
endings penetrating the epidermis) and the hairy skin (black double arrowheads in (d), showing the follicular neural network; white double
arrowheads, showing nerve endings in the dermis and epidermis). Scale bars: 50 𝜇m ((c) = (a); (b); (d)). Figures (b) and (d) are reproduced in
part, and with permission, from [54].
or VGLUT
2
, mainly due to lacking of reliable antibodies.
However, free nerve endings in the mouse palatine mucosa
expressing VGLUT
3
(as well as VGLUT
1
and VGLUT
2
) in
addition to their presence in corpuscular nerve endings and
Merkel cells, have been reported [171]. On the contrary, the
limited number of VGLUT
3
-expressing colorectal [61] and
urinary bladder [62] DRG neurons (identified in VGLUT
3
-
EGFP mice [66]) suggests that only few if any nerve endings
containing this transporter reach those organs. In skin,
peripheral nerve endings produced by VGLUT
3
-expressing
DRG neurons have been recently exposed by the use of
transgenic mice where the reporter gene Tomato is expressed
under the control of theVGLUT
3
promoter [65]. In this study,
VGLUT
3
-expressing DRG neurons were shown to terminate
in the skin in two different fashions: (1) as C-low threshold
mechanoreceptors forming longitudinal lanceolate endings
around hairs, and (2) as epidermal free nerve endings [65].
The neuroanatomy of Tomato-positive fibers innervating
visceral organs remains to be explored.
In accordance with the peptidergic nature of their parent
DRG neurons, the great majority of nerve fibers inner-
vating the colorectal mucosa in the mouse exhibit a high
degree of coexpression of CGRP and VGLUT
2
[61]. This
is in contrast to nerve fibers located in the myenteric
plexus, where most VGLUT
2
and CGRP-IR fibers remained
as different populations [61]. In support, nonpeptidergic
VGLUT
2
-containing varicosities have also been reported
in the esophageal myenteric plexus of rat [161]. Since a
small subpopulation of VGLUT
2
-IR mouse colorectal DRG
neurons is nonpeptidergic (∼18%), it could be postulated
that they selectively innervated the myenteric plexus. Alter-
natively, these nonpeptidergic VGLUT
2
-IR nerve fibers in
the myenteric plexus could derive from neurons in the LSC
or the MPG, two major contributors of nerve fibers in the
colorectum [79] and the urinary bladder [172]. However,
only rarely VGLUT
2
-IR neurons are observed in normal
conditions in these ganglia [61, 62].
Finally, coexpression of VGLUTs in peripheral nerve
endings has been shown for VGLUT
1
and VGLUT
2
in rat
[164] and mouse [165] (but not in guinea pig [163]) IGLEs
[173]. Also, Merkel cells in the rat sinus hair follicle express
VGLUT
2
and often show colocalization with VGLUT
1
[169].
4. Expression of VGLUTs in the Spinal Cord
Thinlymyelinated or unmyelinated low threshold A𝛿- and C-
fibers transmitting nociceptive information and terminating
predominantly in the superficial layers (laminae I and II)
of the spinal dorsal horn release glutamate [174, 175]. Local
spinal cord neurons are also capable of synthesizing and
utilizing glutamate as theirmajor excitatory neurotransmitter
[3, 176, 177]. However, dissecting the patterns of expression
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Figure 5: VGLUTs protein and transcript expressions in the mouse spinal cord. Dark-field ((a) and (c), left side; (e)) and immunofluorescence
((a) and (c), right side; (f)) photomicrographs of sections of the thoracolumbar and lumbar enlargement ((c), (e), (f)) of the spinal cord,
incubated with VGLUT
1
, VGLUT
2
, or VGLUT
3
antisense riboprobes ((a), (c), (e), resp.) or VGLUT
1
(a), VGLUT
2
(c), or EGFP (f) antibodies.
Schematic drawings of the thoracolumbar (b) and lumbar enlargement (d) of the spinal cord are provided as references for the laminae in
the gray matter (taken from The Rat Brain in Stereotaxic Coordinates, Fourth Edition, George Paxinos and Charles Watson, 1998). (a) A
discrete number of VGLUT
1
mRNA-positive NPs are detected in the dorsomedial aspect of the intermediate dorsal horn at thoracolumbar
segments (black double arrowheads) and inmore isolated fashion, in laminae IV-V of the dorsal horn (white double arrowhead). An abundant
VGLUT
1
-IR neuropil is also detected in the dorsal and ventral horns, being more intense in the deep dorsal horn and in area X and only weak
in laminae I-II. (c) Abundant VGLUT
2
mRNA-positive NPs are detected in the lumbar enlargement of the spinal cord, encompassing both
the dorsal and ventral horns. The VGLUT
2
mRNA signal in NPs in laminae II-III appears somewhat more diffuse than in deeper laminae.
The areas occupied by laminae IX are, however, devoid of VGLUT
2
-expressing NPs (asterisk). VGLUT
2
-Li is abundant in the neuropil in
the whole gray matter. ((e), (f)) Only few VGLUT
3
mRNA-positive NPs are detected in laminae III-IV of the dorsal horn (white double
arrowheads in (e)). A modest EGFP-IR neuropil is also observed in laminae II (f). Scale bars: 200𝜇m ((a), (c)) 50𝜇m ((f) = (e)). Figure (f) is
reproduced in part, and with permission, from [66].
and morphology of glutamatergic primary afferent terminals
and spinal cord neurons from a “VGLUT perspective” has
been challenging, mainly due to the failure of virtually all
available VGLUT antibodies to produce immunohistochem-
ical signal in the cell bodies of spinal cord neurons and the
complex contribution of nerve terminals in the area (primary
afferent versus local neurons, dendritic and axonal projec-
tions versus descending fibers). Nevertheless, the combined
knowledge derived from immunohistochemical [30, 40, 46,
48–50, 54, 64, 66, 178–186] and in situ hybridization [43,
48, 51, 136, 187] studies allow today for a rather complete
depiction of the VGLUT scenario in the spinal cord.
Thus, VGLUT
1
- and VGLUT
2
-Lis are easily detected in
the neuropil of the gray matter in the spinal cord, although
both transporters appear distributed differently between
laminae (Figure 5). In rat [30, 40, 46, 48, 50] and mouse [54],
VGLUT
1
-Li is strong in laminae IIi–IV,medial laminaeV/VI,
dorsal lamina VII, and around lamina IX motoneurons. In
contrast, VGLUT
1
-Li is weak in laminae I, IIo, the lateral
part of lamina V, the lateral spinal nucleus, and lamina VIII.
Regarding VGLUT
2
, studies in rat [30, 46, 48, 50] and mouse
[54] exposed its abundant presence in laminae I and IIo, areas
known to receive nociceptive fibers. Deeper in laminae IV-
V, VGLUT
2
-Li appears moderate but progressively increases
towards the ventral horns. As for VGLUT
3
, either through
detection of weak VGLUT
3
and stronger EGFP immuno-
histochemical signals in transgenic mice, presence of the
transporter has been shown in the neuropil of laminae I–
IIi neuropil (Figure 5) [66]. The question is, how are these
different immunohistochemical patterns generated?
DRG neurons are undoubted contributors of VGLUT
1
-
containing nerve fibers in the spinal cord. Varoqui et al. [30]
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were the first in suggesting this and later confirmed by studies
showing that transganglionically labelled primary afferent
terminals in the dorsal horn of the spinal cord of rat expressed
VGLUT
1
- or VGLUT
2
-Li [49]. Further support came from
studies using dorsal rhizotomy, a procedure that completely
blocks the central axonal transport of molecules produced by
DRG neurons. Thus, dorsal rhizotomy dramatically, but not
completely, reduces VGLUT
1
-LI in the ventral horn (and to a
lesser extent also in the dorsal horn), both in rat [46, 48, 50]
and mouse [54].
However, the persistence of at least some VGLUT
1
-Li
after dorsal rhizotomy suggests additional sources, including:
(1) primary afferents expressing this transporter and entering
the spinal cord at levels higher and lower to the lesion and
travelling certain distances before contacting their second
order neurons; (2) local dorsal horn neurons; (3) brainstem-
[48, 178] and cortical-derived [26, 178, 179] nerve terminals.
Supporting the local origin, oligo- and riboprobe, radioactive
or nonradioactive in situ hybridization studies by Kullander
et al. [187] in neonatal mice, and Oliveira et al. [48] and
Llewellyn-Smith et al. [40] in adult rats, revealed a few large
VGLUT
1
mRNA-positive neurons in the dorsomedial part of
the intermediate zone of the dorsal horn of the thoracic spinal
cord, resembling dorsal nucleus of Clarke neurons. Studies
in adult rats also suggested presence of VGLUT
1
mRNA-
positive neurons in the lamina I of the dorsal horn [51], as
well as in motoneurons (Figure 5) [43, 51]. More recently,
in a study in adult mouse, we confirmed the expression of
VGLUT
1
mRNA in a small group of neurons also resembling
the dorsal nucleus of Clarke, and in occasional deep dorsal
horn neurons at thoracolumbar levels [136]. Other spinal
neurons, including motoneurons or superficial dorsal horn
neurons, lacked VGLUT
1
[136]. The presence of VGLUT
1
in
the dorsal nucleus of Clarke, known to be the origin of the
spinocerebellar pathways [188], is supported by the detection
of abundant VGLUT
1
-Li in nerve fibers terminating in
the anterior and posterior zones of the cerebellum [180],
normally receiving spinocerebellar mossy fibers [181].
With one exception in the rat showing an ipsilateral
decrease [46], dorsal rhizotomy appears unable to alter the
immunoreactivity of VGLUT
2
in the dorsal horn of both rat
[48, 50] and mouse [54]. This suggested that most if not all
VGLUT
2
-Li was dependent on local or supraspinal neurons.
In fact, supraspinal sources of VGLUT
2
in the spinal cord
have been recently demonstrated, as shown by their immuno-
histochemical presence in rubrospinal, vestibulospinal and
reticulospinal tracts in rat [178]. However, a great proportion
of VGLUT
2
-Li in the spinal cord is likely dependent on
numerous spinal cord neurons, as shown by their expression
of VGLUT
2
transcript in the ventral and lateral aspects of
the intermediate zone, in discrete parts of the ventral horns,
and in the dorsal horn in rats [40, 48] and mice [136, 187]
(Figure 5).
VGLUT
2
mRNA-positive neurons in the spinal cord
likely belong to both the interneuron [48, 49] and pro-
jection neuron subpopulations [40, 48, 51, 136]. On one
hand, interneurons in the rat spinal cord of rat expressing
somatostatin, neurotensin, substance P, and/or enkephalin
coexpress VGLUT
2
[49]. More recently, functionally iden-
tified excitatory interneurons in the rat have been shown
to express VGLUT
2
-Li [177, 182, 183]. On the other hand,
the presence of VGLUT
2
-Li in the large lemniscal and
spinothalamic terminals to the ventral posterior thalamic
nuclei in the rat [184] confirms that at least a number of
neurons expressing VGLUT
2
mRNA in the rat and mouse
dorsal horn are projection neurons.Moreover, and as pointed
out above, coexpression of both VGLUT
1
- and VGLUT
2
-Lis
in mossy fibers in the cerebellum [180] indicates that Clarke’s
nucleus projection neurons also express VGLUT
2
. Finally,
with the exception of one study in rat, suggesting that both
VGLUT
1
and VGLUT
2
are expressed in motoneurons [43],
other studies in rat [40, 48] and mouse [54, 136, 187] report
thatmotoneurons, as well as neurons in area X, lackVGLUT
2
,
at least at the lumbar enlargement. However, motoneurons
express other glutamatergic markers such as glutamate itself
[185, 189] and/or EAAT-3 [185] and thus may utilize a yet
undescribed VGLUT.
Is then the contribution of primary afferents to the
VGLUT
2
-Li in the dorsal horn of the spinal cord completely
ruled out? The answer is no since VGLUT
2
has indeed
been identified in transganglionically labelled primary affer-
ents in the dorsal horn [49], and it modestly accumulates
after dorsal root ligation (DRG side of the ligation) [54].
It is thus possible that low quantities of VGLUT
2
were
transported by the central projections of DRG neurons and
that the intense local- and supraspinal-dependent VGLUT
2
-
Li in the spinal cord neuropil acted as a masking factor,
potentially explaining lack of changes after dorsal rhizotomy
[46]. Interestingly, the neuropeptide tyrosine receptor type 1
(Y
1
R), normally expressed by small primary afferent neurons,
undergoes axonal transport and can be immunohistochem-
ically detected in the dorsal horn, but its signal remains
unaffected by dorsal rhizotomy [190]. In this case, and as
discussed for VGLUT
2
, the abundant expression of the Y
1
R
in local dorsal horn neurons appears to mask the expected
decrease of the receptor after dorsal rhizotomy [190].
As for VGLUT
3
, its modest immunohistochemical detec-
tion in the superficial dorsal horn has been shown to depend
on DRG and to a lesser extent also supraspinal and spinal
cord neurons. Thus, (1) dorsal rhizotomy in transgenic mice
results in an almost complete disappearance of VGLUT
3
-
regulated EGFP-Li, normally observed in the superficial
laminae of the dorsal horn, certifying its peripheral origin
[66]; (2)Oliveira et al. [48], reported presence of a VGLUT
3
-
IR neuropil in the sympathetic intermediolateral column
(often coexpressing serotonin), supporting their origin in the
dorsal and median raphe nucleus, where such localization
has already been demonstrated [32, 33]; and (3) VGLUT
3
protein [51, 136] and transcript [32, 51, 65, 136] have been
demonstrated in the spinal cord of rat [32, 51] andmouse [65,
136], by means of RT-PCR [32] and western blot [51] in spinal
cord extracts and by in situ hybridization in tissue sections
[51, 65, 136]. More specifically, VGLUT
3
-expressing neurons
have been detected in neurons in the deep dorsal horn and
some in the ventral horn of adult rats [51], in the superficial
and deep dorsal horn of neonatal mice [65], and in the
deep dorsal horn of adult mice [136] (Figure 5). Interestingly,
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the VGLUT
3
-expressing subpopulation of neurons in the
superficial layers of the dorsal horn described by Lou et al.
in the neonatal mouse [65] is not detected in the adult mouse
[136], suggesting developmental regulation of the transporter.
The complex peptidergic versus nonpeptidergic represen-
tation of VGLUTs in DRG neurons is also observed in their
spinal axonal terminations. The general consensus is that
VGLUT
2
is often associated with peptidergic nerve terminals
[46], whereas VGLUT
1
is hardly so [48]. Thus, Li et al. [46]
reported that SP-Li is present in ∼50% of the VGLUT
2
-
IR primary afferent boutons in laminae II [46]. In support,
functional CGRP and AMPA receptors colocalize in single
dorsal horn neurons, suggesting that these neurons may
receive contacts from primary afferent terminals expressing
peptides, glutamate, or both [191]. More importantly, AMPA
receptor GluR
2
-IR puncta can be seen in contact with over
90% of CGRP-IR primary afferent synaptic boutons [192].
However, Todd et al. [49] reported that peptidergic primary
afferents in the rat, as well as nonpeptidergic C-fibers, exhibit
low levels of VGLUT
2
-Li or even lack either VGLUT
1
or
VGLUT
2
.
Finally, and as observed in mouse DRG neuronal bodies
[54], VGLUT
1
and VGLUT
2
colocalization is also detected in
a proportion of primary afferent varicosities in laminae III-
IV and IX in the rat spinal cord [49, 50, 179], as well as in the
nucleus of the solitary tract [186]. The appearance of these
varicosities is described as being “. . .relatively large. . . and
contained immunoreactivity that was intense for VGLUT
1
but weak for VGLUT
2
” [50].
5. Expression of VGLUTs in
Autonomic Ganglia
5.1. Sympathetic and Parasympathetic Ganglia. In normal
conditions, LSC neurons do not express VGLUTs [60–62],
whereas only occasional VGLUT
2
-IR neurons are detected
in naı¨ve mouse MPG [61, 62]. However, VGLUT
2
-IR fibers
are found in the mouse LSC and the MPG, in the latter
forming perineuronal baskets (Figure 3) [60–62], often but
not exclusively, around TH-IR MPG neurons [60].
The VGLUT
2
-IR baskets observed in MPGs appear
greatly dependent on extrinsic sources, as demonstrated
by their dramatic immunohistochemical disappearance after
axotomy of the pelvic nerve [60]. A sympathetic or parasym-
pathetic preganglionic origin [80] for these VGLUT
2
-IR bas-
kets has been ruled out due to their lack of coexpression with
TH or VAChT, respectively. Alternatively, they could derive
from primary afferent fibers in their way to pelvic organs and
also running through the MPG [80, 193, 194]. In support,
Aı¨oun and Rampin [195] have shown the ultrastructural
coexistence of glutamate and large dense core vesicles; the
latter typically loaded with peptides, in axons and terminals
in the rat MPG. In the mouse, however, VGLUT
2
-IR MPG
baskets lack CGRP [60]. Nevertheless, as described above,
many nonpeptidergic mouse visceral DRG neurons express
VGLUT
2
[61, 62].WhetherVGLUT
2
-IRnonpeptidergicDRG
neurons are both the origin of the MPG baskets, as well as
of the neuropil surrounding myenteric plexus neurons in
the mouse colorectum (see Section 3.4), and participate in
sensory-motor coupling remains to be demonstrated. Finally,
one additional source could be viscerofugal neurons project-
ing towards the MPG, found in rat [196], guinea pig [197],
and mouse [198]. Interestingly, we recently showed a small
subpopulation of myenteric neurons expressing VGLUT
2
mRNA in the mouse colorectum [61] (see below).
5.2. Enteric Neurons. Most studies analyzing the expression
of glutamate and glutamatergic markers in enteric neurons
have focused on proximal rather than distal parts of the gut.
Thus, enteric neurons containing immunohistochemically
detectable glutamate have been described in the myenteric
and submucosal plexuses of rat [168] and guinea pig ileum
[168, 199], as well as in myenteric ganglia of the rat stomach
[200]. More recently, a study in humans suggested that
glutamate was present in large intestine submucosal and
myenteric plexuses as well as in nerve fibers innervating
the circular muscle layer [201], supporting earlier studies
showing basal as well as stimulated (electrical and chemical)
release of glutamate presumably from longitudinal muscle
myenteric plexus neurons in the guinea pig ileum [202, 203].
As expected, VGLUTs are detected in enteric neurons
in the gut. Thus, VGLUT
1
was found in cholinergic and
nitrergic neurons in rat [161, 164] andmouse [165] esophageal
myenteric plexus. VGLUT
2
was reported in neurons in the
guinea pig, rat, mouse ileum [44, 204] and in rat [164]
and mouse [162, 164] esophagus. Even in humans, all three
VGLUTs appear to be present in the small intestinemyenteric
plexus neurons, interganglionic varicose fibers, and periso-
matic puncta [205]. In the distal gut, lack of signal of VGLUT
1
and VGLUT
2
in enteric neurons of guinea pig rectum first
suggested absence of glutamatergic enteric neurons, at least
in this species [166]. In mouse, however, both protein and
transcript of VGLUT
2
are found in a small number of
colorectal myenteric plexus neurons, scattered throughout
the plexus in contrast to VGLUT
1
[61] or VGLUT
3
(Figure 3),
which appear to be absent. What the phenotype of VGLUT
2
-
expressing mouse myenteric plexus neurons is, remains
to be established. However, glutamate and substance P or
choline acetyltransferase colocalization was reported in small
intestine enteric neurons of the guinea pig and rat [168].
6. Effects of Peripheral Nerve Injury or Tissue
Inflammation on the Expression of VGLUTs
6.1. Sensory Ganglia and the Spinal Cord. Peripheral nerve
injury [84, 207–209] as well as peripheral tissue inflamma-
tion [210–212] induces downregulation and upregulation of
numerous molecules involved in a variety of functions that
include survival, regeneration, and pain transmission inDRG
and sympathetic ganglia neurons, as well as motoneurons in
the spinal cord [84]. In line with such changes, Al-Ghoul et
al. [213] reported an increase in the immunohistochemical
levels of glutamate in the superficial layers of the dorsal horn
after chronic loose ligation of the sciatic nerve, in parallel
with the expected decrease of substance P and CGRP. Such
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Table 5: Changes in the expression of VGLUTs in DRGs, spinal cord, and/or LSCs, upon peripheral nerve injury (axotomy of the sciatic
nerve) or hindpaw inflammation.
Tissue Species Lesion type Protein mRNA
VGLUT1 VGLUT2 VGLUT3 VGLUT1 VGLUT2 VGLUT3
DRG
Mouse Axotomy 󳶃󳶃 [54] 󳶃 [54]
𝛼 NE No change [136] No change [136] 󳶃 [136]
Hind. inflam. NE NE NE No change [136] No change [136] No change [136]
Rat Axotomy NE NE NE NE NE NE
Hind. inflam. NE NE NE NE NE NE
Spinal
cord
Mouse Axotomy
󳶃󳶃󳶃
(LII-VIII,
IX) [54]
No change [54] NE No change [136] No change [136] No change [136]
Hind. inflam. NE NE NE No change [136] No change [136] No change [136]
Rat Axotomy
󳶃󳶃󳶃 (LII-
VIII-IX)
[214]
NE NE NE NE NE
Hind. inflam. NE NE NE NE NE NE
LSC
Mouse Axotomy
No change
[60] 󳵳 [60] NE No change [60] 󳵳 [60] No change
∗
Hind. inflam. NE NE NE NE NE NE
Rat Axotomy NE NE NE NE NE NE
Hind. inflam. NE NE NE NE NE NE
Arrowhead up: upregulation; arrowhead down: downregulation; NE: not evaluated; 𝛼: plus an increase in VGLUT2-LI in small neuron profiles;
∗unpublished
data; tissue has been processed and NPs quantified according to references [54, 60–62].
increase could be related to alterations in VGLUTs synthesis
and axonal transport.
In fact, peripheral nerve lesions alter the expression of
VGLUTs in primary afferent neurons (Table 5).Thus, Hughes
et al. [214] were the first in demonstrating that axotomy
of the sciatic nerve in rats induces depletion of VGLUT
1
protein in myelinated low threshold cutaneous and muscle
mechanoreceptors terminating in the dorsal and ventral
horns. It is now known that the depletion of VGLUT
1
in
the spinal cord is mainly due to its reduced expression in
DRG neurons, as shown in mouse [54]. Axotomy of the
sciatic nerve in the mouse also reduces the numbers of
VGLUT
2
-IR DRG NPs, although a concomitant increase of
VGLUT
2
-Li was detected in a subpopulation of small DRG
NPs [54]. However, and in contrast to VGLUT
1
, changes in
VGLUT
2
expression in DRGs do not translate into expected
decreases/increases in VGLUT
2
-Li at the lumbar levels of the
spinal cord [54]. As explained for the lack of effect of dorsal
rhizotomy on VGLUT
2
-Li in Section 4, such a “failure” could
relate to what appears to be a modest transport of VGLUT
2
from DRG neurons to the spinal cord [54], the abundant
VGLUT
2
-expression by local dorsal horn neurons [48–50, 53,
54, 136] and the presence of the transporter in descending
pathways [178]. A similar “failure” to detect changes after
axotomy of the sciatic nerve was previously reported in rat
for the Y
1
R in the superficial layers of the dorsal horn [215].
Somewhat surprisingly, the changes in immunohisto-
chemical expression of VGLUT
1
and VGLUT
2
in DRG
neurons appear to find no correlation in the expression of
the corresponding transcripts.Thus, the number ofVGLUT
1
-
or VGLUT
2
mRNA-positive DRGNPs remained unaltered in
mice after a 7-day axotomy [136]. The only observed change
was a modest downregulation in the number of VGLUT
3
mRNA-positive DRG NPs [136], although it is not known
if axotomy also alters its protein expression. It is possible
that differences in the techniques (in situ hybridization versus
immunohistochemistry) and mouse strains (BalbC versus
NMRI mice) between studies explained the discrepancy.
However, it is also possible that differences between transcript
and protein regulations in DRG neurons after peripheral
nerve injury had biological meaning (see Section 7).
Finally, in the only published account so far, inflamma-
tion of the hindpaw (using a unilateral intradermal injection
of Complete Freund’s Adjuvant) failed to induce changes in
the expression ofVGLUT
1
, VGLUT
2
, orVGLUT
3
transcripts,
both in DRG or spinal cord neurons [136]. Perhaps in these
conditions, changes in expression and physiology of VGLUTs
are more relevant in the axon and synaptic zones, where
glutamate concentration and production is 2 to 3 times higher
than in the cell body [19, 216, 217]. However, whether the
inflammation of the hindpaw (or visceral organs) results
in changes in VGLUT proteins in DRG neurons and their
projections remains to be established.
6.2. Sympathetic Ganglia. Sympathetic neurons are pro-
foundly affected by peripheral nerve injury [84, 101, 102, 209].
Thus, postganglionic axotomy of sympathetic nerves in cat
LSC [218] or rodent superior cervical ganglion (SCG) [101,
102, 206] induces downregulation of neuropeptides such as
CGRP [218] andNPY, aswell as the noradrenergicmarker TH
[101, 102, 219, 220], and upregulation of galanin [101, 102, 218],
VIP, SP [101, 102, 221], and the NPY Y
2
-receptor [101, 102,
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VGLUT2 + ATF-3
LSC
Pelvic nerve axotomy
(a)
VGLUT2 + TH
(b)
Figure 6: VGLUT2 is upregulated in LSC neurons and occasionally coexpresses with TH. Immunofluorescence photomicrographs of sections
of the LSC of mouse after pelvic nerve axotomy, incubated with VGLUT
2
((a), (b)) and ATF-3 (a) or TH (b) antibodies. ATF-3 is used as a
marker of injured neurons. (a) Pelvic nerve axotomy results in de novo expression ofATF-3 in an abundant number of LSCNPs (arrows). Pelvic
nerve axotomy also results in de novo upregulation of VGLUT
2
, always coincidental with the upregulation of ATF-3 (double arrowheads).
(b) Most VGLUT
2
-IR LSC NPs observed after lesion lack TH (arrowheads), although occasional VGLUT
2
/TH-IR NPs are detected (double
arrowhead). Abundant TH-IR NPs are present in the LSC (arrows). Scale bars: 10 𝜇m.
206]. Also in pigs, the axotomy of colonic nerves containing
sympathetic fibers projecting from the LSC, results in the
upregulation of galanin and somatostatin, paralleled by the
downregulation of TH [222].
Only until recently, glutamate was not thought to be
present in autonomic neurons [81]. In fact, apart from a few
VGLUT
2
-IR nerve fibers present in LSCs (more abundant
in the stellate ganglion; unpublished results), VGLUTs are
not normally expressed by neurons in these ganglia [60–62].
However, axotomy of either the pelvic (visceral) or the sciatic
(nonvisceral) nerves results in the upregulation of VGLUT
2
in a number of mouse LSC neurons (Table 5, Figure 6) [60].
The lesion-induced VGLUT
2
plasticity appears to be selective
in that parallel VGLUT
1
protein and transcript or VGLUT
3
mRNA upregulations are not observed [136]. The majority
of VGLUT
2
-IR LSC neurons detected after injury lack TH,
suggesting a parallel downregulation of the noradrenergic
marker (see above). However, some LSC neurons upregulat-
ing VGLUT
2
were shown to coexpress with TH, suggesting
the possibility of glutamate and noradrenaline corelease [60]
(Figure 6). Coexpression of VGLUT
2
[223–228] or glutamate
[223] with TH (used as a marker for dopaminergic neurons)
has been previously shown in rat [223, 225–228] brainstem
and hypothalamus [228]. Alternatively, VGLUT
2
could be
upregulated in LSC cholinergic (nonnoradrenergic) neurons
[229], although this remains to be demonstrated.
The upregulation of VGLUT
2
in LSC neurons could
represent de novo synthesis of transporter protein and tran-
script, or an increase from low, undetectable levels. The
absence of VGLUT
2
(or other VGLUTs) transcript, using the
sensitive riboprobe in situ hybridization techniques suggests
the former hypothesis [60]. Considering the importance of
VGLUTs for the uploading of glutamate into synaptic vesicles,
it could be speculated that some LSC neurons, upon injury,
acquire a glutamatergic phenotype, may release glutamate,
and could potentially contribute to increased fast synaptic
transmission and nociceptive mechanisms [60].
7. VGLUTs Modulation after
Peripheral Nerve Injury—Implications to
Glutamatergic Neurotransmission
While it is still not known exactly how many VGLUT
copies are in each synaptic vesicle [35], it seems intuitive
that changes in their expression after tissue insult should
have profound consequences in glutamate loading. In fact,
several studies where the expression of VGLUTs in synaptic
vesicles is genetically manipulated suggest that the type
and/or number of VGLUTs matter [19, 35]. For instance, the
number of VGLUT copies in a given synaptic vesicle/neuron
influences the amount and rate of vesicle loading, the size of
glutamatergic quanta, and even the reserve pool of synaptic
vesicles [158, 230–232].
In line with the above, the downregulation of VGLUT
1
[214] and VGLUT
2
proteins [54] observed in DRG neurons
after sciatic nerve axotomy, while maintaining unaltered
mRNA levels [136], may imply that these neurons sustain
transcriptional levels of VGLUT
1
and VGLUT
2
, in order
to counteract the downregulation at the cell body level
the latter resulting from increased axonal transport, protein
use, and depletion at peripheral and central terminals [54].
Interestingly, axotomy of the sciatic nerve in rats results in a
reduction in the number of synaptic vesicles in the central
terminals of axotomized primary afferents [233], including
peptidergic ones [234], suggesting increased fusion of clear
synaptic vesicles (likely expressing VGLUTs) to the plasma
membrane and glutamatergic release.
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However, it should be noted that glutamatergic neu-
rotransmission, from a synaptic vesicle point of view, is
influenced by a variety of additional factors, comprising: (1)
several steps to produce mature synaptic vesicles, mostly
at the axons, although some may already happen in the
soma [235]; (2) an active and tight regulation of presynaptic
vesicle and transmitter recycling at the level of the synaptic
cleft, to counteract depletion in situations of high activity
[19, 216, 236]; (3) the extravesicular/cytoplasmic glutamate
concentration (regulated by the enzyme glutaminase) 2 to 3
times higher in the terminals than in the cell body [217] and
crucial in defining intravesicular glutamate content [19, 216];
(4) chloride conductance, along with the synaptic membrane
potential, as also determining the glutamatergic content of
synaptic vesicles and involving the participation of VGLUTs
[237]; and (5) vesicular size, as it has been shown that there are
different naturally occurring sizes that influence the quanta
for different neurotransmitters, including glutamate [238].
How all these factors are challenged by peripheral nerve
or tissue injury is not yet known. However, it has been
shown that glutaminase is upregulated in rat DRG neurons
during hindpaw inflammation and that its blockade results
in reduced pain-like behaviour [239].
Altogether, nerve injury and/or inflammation and the
accompanying pain, may result from changes in the expres-
sion of synaptic vesicles, associated proteins (including
VGLUTs) and neuronal glutamatergic machinery in general,
contributing to a fine “tuning” of pain mechanisms both at
the synaptic as well as the cell body levels (see below).
8. VGLUTs, Proprioception, Pain, Survival,
and Neuroprotection
8.1. Proprioception. Different studies in the peripheral and
nervous systems suggest that proprioception is served by
glutamatergic neurons expressing VGLUTs. This hypothesis
is based on many of the observations in rodents presented
above: (1) VGLUT
1
is expressed by a number of large and
medium-sized DRG neurons [48, 51, 54] likely producing
myelinated peripheral projections terminating in muscle
and joint proprioceptors; (2) VGLUT
1
-IR DRG neurons
project fibers that have been morphologically characterized
as proprioceptive [50, 214] towards the ventral horn and
establish primary afferent-motoneuron contacts [40, 48–51,
54, 187, 214]; (3) many VGLUT
1
-IR (likely proprioceptive)
fibers also terminate in the deep dorsal horn, in the area
occupied by Clarke’s nucleus [48, 50, 54, 136, 187]; (4) Clarke’s
nucleus, composed by the second-order neurons giving rise
to the spinocerebellar proprioceptive pathway [188] expresses
VGLUT
1
[40, 48, 136, 187], and likely also VGLUT
2
[136,
180]; (5) VGLUT
1
-Li (and also VGLUT
2
) is detected in
mossy fibers terminating in the anterior and posterior zones
of the cerebellum [180], known to receive input from the
spinocerebellar pathway described above [181]. In addition,
and suggesting a role in the cortical control of motoneurons,
pyramidal cells in the neocortex express VGLUT
1
mRNA
[26], and numerous rat corticospinal tract nerve fibers ter-
minating in the ventral horns exhibit VGLUT
1
-Li [178, 179].
8.2. Nonvisceral Pain. Theuse of transgenicmice has exposed
a central role for VGLUT
2
in the glutamatergic mechanisms
associated to nonvisceral pain. Thus, heterozygote VGLUT
2
knock-out (KO) mice (homozygote mice experience peri-
natal death) exhibit impaired mechanical and cold allody-
nia after spared sciatic nerve injury, despite maintaining
normal acute pain responses and increases in pain-like
behaviour after inflammation of the hindpaw [240, 241]. Such
behavioural patterns after partial VGLUT
2
-KO originally
suggested the involvement of the thalamus, whose neurons
are richly provided with VGLUT
2
and presented with altered
electrophysiological function in the transgenic mice [241].
However, mechanisms involving VGLUT
2
and pain appear
to be relevant also at the DRG level. Thus, the selective
deletion of VGLUT
2
in a subpopulation of TH- and TRPV
1
-
expressing neurons inmouse DRGs resulted in increased itch
and decreased thermal pain sensitivity [155]. Interestingly,
peripheral nerve injury results in VGLUT
2
-Li increases in
small mouse DRG neurons [54] (see Section 6.1), and it is
possible that these were TRPV1-expressing (see Section 3.2).
Thus, a hypothesis could be that activation of TRPV
1
in
neurons upregulating VGLUT
2
during peripheral neuropa-
thy may contribute to heightened peripheral and/or central
release of glutamate, in the latter, resulting in the activation
of nociceptive second-order projection neurons present in
laminae I-II [242].
Selective deletion of VGLUT
2
in another subpopulation
of DRG neurons expressing the sodium channel subtype
Nav1.8 resulted in altered pain responses, including atten-
uated responses to intense mechanical stimuli [243]. Inter-
estingly, most of these effects seem to be associated with
reductions in glutamate release in the superficial layers of
the dorsal horn, as shown by the reduced c-fos activation
of local dorsal horn neurons upon noxious heat stimulation
[155] or intraplantar injection of capsaicin [244]. Moreover,
a reduction in spontaneous excitatory postsynaptic currents
was observed in lamina II dorsal horn neurons in the
VGLUT
2
-KO-Nav1.8 mice [244].
Of the other known VGLUTs, VGLUT
1
appears mostly
associated with proprioception (see above) and the transmis-
sion of tactile stimuli, as it has been proposed that many
VGLUT
1
-expressing primary afferent terminals in the super-
ficial and deep dorsal horn correspond to low-threshold cuta-
neousmechanoreceptors, including those associated with the
piloneural complex, in particular for nerve fibers terminating
in lamina IIi of the superficial dorsal horn [49, 50, 214].
Deletion ofVGLUT
1
inmice has no effect onnonvisceral pain
behaviour [240].
On the contrary, VGLUT
3
is currently the center of
debate. On one hand, deletion of VGLUT
3
in mice results
in an increased threshold to intense noxious mechanical
stimuli and reduced mechanical hypersensitivity to normally
innocuous stimuli after tissue inflammation or nerve injury
[66]. On the other hand, mice with deleted VGLUT
3
through
knockout of the runt domain transcription factor Runx1,
essential for the developmental control of unmyelinated sen-
sory neurons (nociceptors, pruriceptors, and thermoceptors)
[245] and alsoVGLUT
3
in sensory neurons [65], did not show
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major changes in acute and chronicmechanical pain, with the
exception of a modest increase in mechanical threshold after
hindpaw carrageenan injection [65]. However, Seal et al. [66]
utilized mice with global VGLUT
3
knockout (these mice also
having deafness and rare nonconvulsive seizures), and thus,
the behavioural effects observed in their study could also be
influenced by deletion of the transporter in the spinal cord
or other parts of the brain. With some limitations as well, the
study by Lou et al. [65] analyzedneurons lackingVGLUT
3
but
also Runx1, the latter influencing the expression of additional
molecules in sensory neurons. Therefore, more research is
needed to better understand the role of VGLUT
3
in acute and
chronic nonvisceral pain.
Finally, the role of VGLUTs in nonvisceral nociception
may also extend into the peripheral projections of DRG
neurons. This is suggested by the increased glutamate (but
not aspartate) levels in the hindpaw extracellular space, upon
A- and/or C-fiber stimulation of the sciatic nerve, as well
as the local injection of kainate or capsaicin [246]. Such a
release of glutamate results in depolarizing effects on primary
afferent C-fibers and the induction of pain-related behaviour
of exogenously applied glutamate [246–249], likely acting on
presynaptic glutamate (auto) receptors of various types [250–
254]. The type of VGLUT involved in these mechanisms has
not been defined. However, it is possible that VGLUT
2
was
a main player, as suggested by its abundance in peripheral
nerve endings in the skin [54].
8.3. Visceral Pain. The involvement of VGLUTs in visceral
pain remains to be elucidated. The only study on the role of
VGLUT
2
in visceral pain published so far found no differ-
ences between VGLUT
2
-KO and littermate mice [240]. This
is curious, especially when considering that the abundant
numbers of VGLUT
2
-expressing colorectal [61] and urinary
bladder [62] neurons imply the likely colocalization of the
transporter with several molecules associated with nocicep-
tion, such as TRPV
1
[89], P
2
X
3
[90], or the sodium channel
NaV1.8 [91], only to cite a few. Thus, TRPV
1
is abundantly
expressed in rat andmouse colorectal DRG neurons [76, 255]
and has been associated to mechanisms of chronic visceral
pain [256], and coexpression of VGLUT
2
with TRPV
1
has
been previously reported in nerve fibers terminating in
the mouse rectum [167]. In addition, P
2
X
3
, implicated in
nociception [257], particularly in visceral organs [258, 259],
is also expressed by a proportion of colorectal DRG neurons
[77], and a role for Na(v)1.8 in visceral pain and hyperalgesia
has also been reported [260].Therefore, it would be expected
that deletion of VGLUT
2
in somany neurons clearly prepared
for nociception resulted in altered pain mechanisms. More
research will be necessary to establish the extent to which
VGLUT
2
participates in the physiopathology of visceral
disorders associated with discomfort and pain.
Finally, preliminary experiments suggest that VGLUT
3
may not be involved in visceral hypersensitivity since its
deletion does not alter the response to noxious mechanical
distension of the colorectum, as compared to control mice
(unpublished results). Accordingly, only a small percentage of
VGLUT
3
-expressing DRG neurons innervating the urinary
bladder [62] or the colorectum (Figure 1) have been identi-
fied. However, an association between changes in the expres-
sion of VGLUT
3
in DRG neurons and visceral hyperalgesia
in rats with Trichinella Spiralis infection has been proposed
[64].
8.4. VGLUT-Expressing Sympathetic Neurons: Implications to
Pain. The upregulation of VGLUT
2
in sympathetic neurons
in the LSC (see Section 6.2) positions them as the new
“kid on the block”, acting as one additional contributor to
peripherally released glutamate [60], along with primary
afferents [48, 51, 53, 54, 54, 61, 62, 66, 154], and participating in
processes of sympathetic-sensory neuron coupling [261, 262],
also through glutamatergic neurotransmission.
In such scenario, glutamate released from primary affer-
ent nerve terminals could act onto various types of glu-
tamatergic receptors present in sympathetic postganglionic
nerves [263–266], promoting an augmented release of nora-
drenaline and perhaps also glutamate. In turn, such “sym-
pathetically” released glutamate could act on existing gluta-
matergic receptors in both visceral [267–270] andnonvisceral
[175, 253, 271–275] primary afferent neurons, perpetuating a
state of excitation in conditions such as inflammation [266]
or nerve injury. More research will be necessary to: (1) assess
the role of nerve injury-induced upregulation of VGLUT
2
in
LSC neurons; (2) explore if its expression is also affected by
other types of visceral organs pathological conditions (e.g.,
ulcerative colitis or interstitial cystitis); and (3) what is the
consequence of deleting VGLUT
2
on autonomically driven
nociceptive mechanisms.
8.5. VGLUTs, Survival, and Neuroprotection. The increased
expression of VGLUT
2
in LSCneurons appears tightly related
to the occurrence of axonal damage, as shown by the con-
comitant upregulation of the activating transcription factor
3 (ATF-3) [60] (Figure 6), a classical marker of damaged
peripheral axons [276]. Axotomy of the rat ormouse superior
cervical ganglion postganglionic axons also results in de
novo ATF-3 expression [277], although it is not known if
VGLUT
2
is upregulated in these neurons. Interestingly, ATF-
3 [278], as well as the classical nerve growth factor (NGF), are
central to mechanisms of nerve regeneration, and neuronal
survival [80, 209]. Whether the upregulated VGLUT
2
(and
potentially also glutamate) had a role in the survival and
regeneration of LSC neurons remains to be established. How-
ever, several studies support such concept.Thus, VGLUT
2
-Li
is present in neurons migrating from the olfactory placode
towards the forebrain in the developing rat brain, gradually
decreasing toward adulthood [279]. Moreover, an association
between the expression of VGLUT
2
protein inmesencephalic
dopaminergic (DA) neurons and their formation of synaptic
junctions in the nucleus accumbens was demonstrated in
rat [280]. Furthermore, conditional knockout of VGLUT
2
results in reduced growth and survival of mesencephalic
DA neurons, decrease in the density of DA innervation
in the nucleus accumbens, reduced activity-dependent DA
release, and impaired motor behaviour [281]. Thus, despite
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the established concept that excessive activation of gluta-
matergic receptors results in neurotoxicity [282], in certain
cases glutamate could have the opposite effect and contribute
to survival and neuroprotection [283].
Interestingly, VGLUTs may also serve a role in devel-
opment and neuroprotection in DRG neurons, as suggested
in a recent study showing that glutamate release is essential
to the development, maintenance, and sensory function of
the piloneural mechanoreceptor, with VGLUT
2
being a key
player [284].
9. Could VGLUTs Become Pharmacological
Targets for the Control of Pain?
Throughout this review, we have highlighted the current
knowledge on VGLUTs in peripheral neurons and the spinal
cord, their regulation by tissue injury, and their involve-
ment in sensation and pain. The abundance of VGLUT
2
in
the periphery implies a fundamental role in glutamatergic
physiology, even though the more discrete expression of
VGLUT
1
and VGLUT
3
also suggests specific roles in select
groups of DRG neurons. Data in transgenic mice, where a
50% reduction in VGLUT
2
[155, 240, 241, 243] or total abla-
tion of VGLUT
3
[66] protein results in reduced/attenuated
mechanical and cold hyperalgesia/allodynia after peripheral
nerve injury or nonvisceral inflammation, while leaving
unaffected other types of sensory processing, including acute
nociception and inflammatory hyperalgesia, are compelling.
Based on this knowledge, pharmacological blockade (total
or partial) of VGLUT activity could efficiently reduce the
amount of glutamate per vesicle, affect the size of glutamater-
gic quanta [241, 285, 286], and thus, attenuate glutamatergic
neurotransmission, both at central and/or peripheral sites,
resulting in the reduction of pain.
Exogenous VGLUT inhibitors, such as Chicago sky blue
6B (CSB6B), have been shown to inhibit the loading of
glutamate into synaptic vesicles upon intracerebroventricular
application [287], resulting in the inhibition of the metham-
phetamine induced hyperlocomotion and behavioural sensi-
tization [288]. Interestingly, in an older study, Beirith et al.
[289] evaluated the role of a systemically delivered CSB6B
in animals receiving an intraplantar injection of glutamate
and found that the use of the VGLUT inhibitor results in
a considerable reduction of glutamate-induced nociception.
However, the site of action of systemically applied CSB6B
was not evaluated in that study, and thus, whether the
inhibition of vesicular glutamate uptake occurs at peripheral
nerve endings, spinal cord, supraspinal levels, or all of them
remains to be established. Other exogenous compounds,
including the dye Evans Blue or the Bengal Rose extract,
have been described as VGLUT inhibitors and await further
characterization [290, 291].
Endogenous VGLUT regulators also exist. Thus, fasting
or diets with high lipidic and low glucose content (ketogenic
diet), originally used to successfully reduce epileptic seizures
[292], result in reduced pain and inflammation in juvenile
and adult rats [292, 293]. Interestingly, the mechanisms of
action proposed for ketogenic diets include decreases in
the intracellular glutamatergic pool, as shown in cultured
cerebellar granule neurons [294] and of glutamate uptake in
synaptic vesicles by interference with the VGLUT chloride
binding sites described in Section 7 [295]. However, the
possible association of ketogenic diets, VGLUTs modulation,
glutamate vesicular loading and pain mechanisms remain
to be further established. Finally, different products of the
kynurenine pathway in the metabolism of the amino acid
tryptophan have been shown to exert antinociceptive roles
after intraperitoneal administration in rats [296, 297], pos-
sibly through inhibition of VGLUTs activity [298].
Synthetic VGLUT inhibitors have been recently devel-
oped and their blocking action demonstrated in vitro [299,
300]. Unfortunately, these inhibitors do not discriminate
between VGLUT types, and their role in vivo has yet to be
determined. The development of selective VGLUT antag-
onists not only could help in dissecting the role of each
VGLUT in in vitro and in vivo studies, but could also be
therapeutically interesting, since regulation of the quantal
size before fusion to the plasma membrane is emerging as
an attractive approach to regulate the function of several
neurotransmitters and as a tool to generate new pharma-
cological compounds [19, 301]. It is noteworthy that com-
mercially available anticonvulsant agents such as gabapentin,
lamotrigine, and riluzole limit glutamate release as part of
their mechanisms of action and have been shown to be
effective in reducing hyperalgesia in rats with neuropathy
[302]. However, whether these agents act onVGLUTs to affect
glutamate release is currently unknown.
The reduction of pain behaviour by topical targeting of
peripheral glutamatergic mechanisms should also be consid-
ered. Thus, blockade of peripheral glutamatergic receptors
emerge as an interesting therapeutic option [253, 270, 274,
303, 304], especially in view of the complex and serious CNS-
driven side effects of systemically delivered glutamatergic
receptor antagonists [303, 305, 306]. Likewise, inhibiting the
peripheral synthesis of glutamate by targeting glutaminase
bears promise [16]. In fact, glutaminase is upregulated in rat
DRG neurons during inflammatory processes of the hindpaw
[239], and its peripheral inhibition results in a reduction
of the inflammation-induced hindpaw edema and of c-fos
expression in laminae I-II of the dorsal horn of rats, as well
as long-lasting analgesia [307]. Finally, and based on their
abundant peripheral representation (especially for VGLUT
2
),
it is likely that challenging the activity of peripheral VGLUTs
should also result in efficient modulation of glutamatergic
neurotransmission.
10. Summary
In conclusion, this review has addressed various aspects
relating to VGLUTs in visceral and nonvisceral DRGs,
sympathetic neurons, and the spinal cord. When focusing
on some of the functions of VGLUTs, the expression of
VGLUT
1
in primary afferent nerves terminating in spinal
areas such as those occupied by the dorsal nucleus of Clarke
(also VGLUT
1
-expressing) and motoneurons suggests a role
in proprioception, whereas VGLUT
2
, and to some extent
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VGLUT
3
, exhibits a robust association to nociception and
pain. Moreover, the frequent coexpression of VGLUT
2
and
CGRP supports the idea of corelease, and this could be
relevant in processes of neurogenic inflammation. The de
novo expression of VGLUT
2
in the LSC supports previously
unexpected roles, such as sympathetic glutamatergic neuro-
transmission and/or survival and neuroprotection. Finally,
the efficacy of the genetic deletion of VGLUT
2
(even if only
half of what a neuron normally produces) and VGLUT
3
for the control of pain in rodents highlights the potential
of these VGLUTs as potentially interesting targets for the
development of new analgesic compounds. In such line of
thought, it would be important to analyze the presence and
distribution of VGLUTs in human peripheral nervous tissue
and how do they react to tissue or nerve insult.
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VGLUT: Vesicular glutamate transporter
Y1R: Neuropeptide tyrosine receptor, type 1
Y2R: Neuropeptide tyrosine receptor, type 2.
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